A new screening test for lung cancer could prevent thousands of Quebecers invasive biopsy. The blood test was developed by an American company and Caprion, a SME in Montreal. Martin LeBlanc, CEO of Caprion, is the personality of the week of La Presse. Martin LeBlanc is a member of the Board of Directors of the QNPHC. Developed in collaboration with Integrated Diagnostics, a Seattle company, this new blood test permits to evaluate if a lung nodule is benign or malignant. (in French only) >